Xgeva Disease Interactions
There are 2 disease interactions with Xgeva (denosumab).
Denosumab (applies to Xgeva) hypocalcemia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypoparathyroidism, Thyroid Disease, Renal Dysfunction
Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.
References (1)
- (2010) "Product Information. Prolia (denosumab)." Amgen USA
Denosumab (applies to Xgeva) immunosuppression
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
Denosumab should be used with caution in patients with impaired immune systems or taking concomitant immunosuppressant agents as they may be at increased risk for serious infections.
References (1)
- (2010) "Product Information. Prolia (denosumab)." Amgen USA
Switch to consumer interaction data
Xgeva drug interactions
There are 308 drug interactions with Xgeva (denosumab).
Report options
More about Xgeva (denosumab)
- Xgeva consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (9)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: miscellaneous bone resorption inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Prolia
Prolia (denosumab) is an injection that is administered subcutaneously (under the skin) once every ...
Reclast
Reclast (zoledronic acid) is used to treat osteoporosis in women after menopause and also to treat ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Zometa
Zometa is used to treat high blood levels of calcium caused by cancer and multiple myeloma. Learn ...
Wyost
Wyost (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) by a ...
Jubbonti
Jubbonti (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) once ...
Aclasta
Aclasta (zoledronic acid) inhibits the release of calcium from bones and is used to treat Paget's ...
Zoledronic acid
Zoledronic acid is used for hypercalcemia of malignancy, osteolytic bone lesions of multiple ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
